Clinical trial · Interventional
Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer
A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors
NCT01312324CI-TRIAL-00021859completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We try to evaluate whether neoadjuvant docetaxel plus cisplatin can increase the complete resection rate in advanced thymic carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Stage III or IV Thymic Cancer | Thymus Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| neoadjuvant docetaxel/cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- neoadjuvant chemotherapy
- description
- 3 cycles of docetaxel/cisplatin before operation
- interventionNames
- Drug: neoadjuvant docetaxel/cisplatin
Primary outcomes (1)
- measure
- Complete resection rate
- timeFrame
- 4-8 weeks later after completion of neoadjuvant chemotherapy
Secondary outcomes (1)
- measure
- the number of patients with adverse events
- timeFrame
- from enrollment to 6 months after completion of chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed thymic carcinoma * surgically inoperable Masaoka stage III or IV * ECOG 0-2 * at least one measurable disease Exclusion Criteria: * previous myocardiac infarct history within 1 year before the enrollment.
References
Publications (0)
Data not yet available
No reference posted for this study.